Le Lézard
Classified in: Health, Science and technology
Subject: Conference

Compass Therapeutics to Participate in the B. Riley Securities Virtual Oncology Investor Conference


Compass Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer of Compass Therapeutics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference.

The Compass presentation will be live webcast at 10:30 a.m. EST on January 21, 2021. The presentation will be open to registered conference attendees, institutional investors and investor relations professionals, who may register to view the live webcast at https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup. After completion of the event, a replay of the presentation will be publicly available under the "Investors ? Events and Presentations" tab on the Compass website at www.compasstherapeutics.com.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabstm and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The company's lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, and is currently being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. Compass is also progressing several preclinical assets including a novel class of NK cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs.


These press releases may also interest you

at 06:50
Merck , known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then...

at 06:45
RentRedi, an award-winning property management software that simplifies the renting process for both landlords and renters, has expanded its on-time rent reporting to all three major credit bureaus: Equifax, Experian, and TransUnion. The ability to...

at 06:40
Monport, a frontrunner in laser technology innovation, proudly presents its latest marvel: The Monport GPro MOPA Fiber Laser Engraver. This cutting-edge machine is poised to redefine precision marking with its unparalleled capabilities and advanced...

at 06:34
Trip.com Group has announced record bookings in Abu Dhabi, exceeding 57,000 room nights over the past 12 months. Following a strategic partnership signed at the Arabian Travel Market last year, Trip.com Group's comprehensive portfolio of travel...

at 06:31
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual...

at 06:30
Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular...



News published on and distributed by: